BRCA1 and prostate carcinoma: Olaparib has been approved for patients with breast, ovarian, pancreatic, or prostate cancer who had HRD or BRCA1/2 mutations with PVs, whereas niraparib has been approved for patients with ovarian cancer who had HRD or BRCA1/2 mutations with PVs.